Update: Big Pharma Firms Denied Certiorari by Supreme Court in Medicare Pricing Case
Idag, 10:15
04:15 AM EDT, 05/19/2026 (MT Newswires) -- (Updates with Novo Nordisk's response in the fourth and fifth paragraphs.)
The US Supreme Court on Monday denied petitions for writs of certiorari filed by six big pharmaceutical companies seeking to challenge the legality of the so-called 'Drug Price Negotiation Program'under the Inflation Reduction Act of 2022.
AstraZeneca (AZN), Novartis (NVS), Novo Nordisk (NVO), Johnson &Johnson's (JNJ) Janssen Pharmaceuticals, Bristol Myers Squibb (BMY) and Boehringer Ingelheim Pharmaceuticals all had their petitions denied by the Supreme Court.
Novo Nordisk said in an email to MT Newswires that it "remains opposed to government price setting through the Inflation Reduction Act and has significant concerns about the law and with how CMS implemented the statute."
It added that, "Novo Nordisk does not agree with the aggregation of multiple products, which individually would not meet the statute's requirements for selection. We are disappointed with the Supreme Court's decision to not accept the case and will continue to engage with policymakers and regulators to raise our concerns."
The other companies did not respond to requests for comment from MT Newswires.
Update: Big Pharma Firms Denied Certiorari by Supreme Court in Medicare Pricing Case
Idag, 10:15
04:15 AM EDT, 05/19/2026 (MT Newswires) -- (Updates with Novo Nordisk's response in the fourth and fifth paragraphs.)
The US Supreme Court on Monday denied petitions for writs of certiorari filed by six big pharmaceutical companies seeking to challenge the legality of the so-called 'Drug Price Negotiation Program'under the Inflation Reduction Act of 2022.
AstraZeneca (AZN), Novartis (NVS), Novo Nordisk (NVO), Johnson &Johnson's (JNJ) Janssen Pharmaceuticals, Bristol Myers Squibb (BMY) and Boehringer Ingelheim Pharmaceuticals all had their petitions denied by the Supreme Court.
Novo Nordisk said in an email to MT Newswires that it "remains opposed to government price setting through the Inflation Reduction Act and has significant concerns about the law and with how CMS implemented the statute."
It added that, "Novo Nordisk does not agree with the aggregation of multiple products, which individually would not meet the statute's requirements for selection. We are disappointed with the Supreme Court's decision to not accept the case and will continue to engage with policymakers and regulators to raise our concerns."
The other companies did not respond to requests for comment from MT Newswires.
Evolution
Evolution
Marknadsöversikt
1 DAG %
Senast
1 mån
